Perceptions of extended-release buprenorphine among people who received medication for opioid use disorder in jail: a qualitative study.

ABSTRACT:

Background

Incarceration provides an opportunity for health interventions, including opioid use disorder (OUD) treatment and prevention of opioid-related overdoses post-release. All FDA-approved forms of medication for OUD (MOUD) treatment were mandated in several Massachusetts jails in 2019, with some jails offering extended-release buprenorphine (XR-Bup). Little is known about patient perspectives on and experiences with XR-Bup in carceral settings.

Methods

We conducted semi-structured interviews in 2022 with community-dwelling people who received MOUD during a recent incarceration in a Massachusetts jail. We asked participants about their experiences with and perspectives on XR-Bup while in jail. Qualitative data were double-coded deductively and reviewed inductively to i

SUBMITTER: Stopka TJ 

PROVIDER: S-EPMC11395844 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature